FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity…
February, 08 2024 • Articles
SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting
• No serious adverse events in the first two cohorts of patients dosed with SPVN06 (N=6)
• Observed ocular adverse events predominantly procedural, transient and resolved
• SparingVision founder, José-Alain Sahel, MD, awarded the Macula Society Michaelson Award
Paris, 8 February 2024 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, has presented positive initial safety data from the Phase I/II PRODYGY clinical trial of its lead gene-agnostic investigational gene therapy, SPVN06, for the treatment of retinitis pigmentosa (RP). Data from six patients treated with SPVN06 were shared by Professor Isabelle Audo,, Principal Investigator of the study, in an oral presentation at the Macula Society 47th Annual Meeting being held February 7-10, 2024 in Palm Springs, USA.
Initial six-month data on the three patients who received a low dose of SPVN06 showed no serious adverse events, significant inflammation, discontinuation, or dose-limiting toxicity. Additionally, one-month data on the three patients treated with a medium dose corroborated these findings.
Ocular adverse events observed were primarily associated with procedural aspects and resolved swiftly.
Enrollment and treatment of the third cohort, comprising three patients at a higher dose, are underway following a favorable review and positive recommendation from the Data Safety Monitoring Board.
Dr Daniel C. Chung, Chief Medical Officer of SparingVision, said: “The lack of serious adverse effects, discontinuations, or dose-limiting toxicity and no significant inflammation or immune response demonstrated in the preliminary safety data for SPVN06 in our early groups is highly encouraging. This robust safety profile bolsters our confidence as we move forward with the study.”
SPVN06 is a breakthrough gene-agnostic gene therapy approach aimed at stopping or slowing disease progression in patients affected by rod-cone dystrophy (RCD). SparingVision is initially focusing on mid-stage RP, the most common form of RCD and one of the leading inherited causes of blindness globally. The Company aims to investigate the advantages of its gene therapy in treating geographic atrophy (GA) and potentially commence Investigational New Drug (IND)-enabling studies for GA in 2024.
In addition, SparingVision is delighted to announce that its founder, José-Alain Sahel3, MD, has received the Macula Society Michaelson Award, a distinction presented every three years to an outstanding scientist. Pr. Sahel also delivered the Michaelson lecture on gene-independent strategies for retinal degenerations and organized a related symposium at the meeting.
PRODYGY (Promising ROd-cone DYstrophy Gene therapY) is a multicentric Phase I/II trial to assess the safety, tolerability as well as preliminary efficacy and quality-of-life following a single subretinal injection of SPVN06 in the worst-seeing eye of adult patients with RCD due to a mutation in the RHO, PDE6A, or PDE6B gene. Further information on the PRODYGY trial can be found on www.ClinicalTrials.gov (CT identifier: NCT05748873).
Dr. Jose-Alain Sahel and UPMC have financial interests in the study sponsor, SparingVision. These financial interests mean it is possible that the results of this research could lead to personal profit for Dr. Sahel and to institutional profit for UPMC. The conflicts of interest presented by these relationships are being managed by the University and UPMC.
President and CEO
Amber Fennell, Namrata Taak, Davide Salvi
+44 (0)20 3709 5700
NOTES TO EDITORS:
SparingVision is a global ophthalmology leader bringing new hope to millions affected by retinal diseases, for which there are currently no viable treatments. The Company has assembled a suite of cutting-edge technologies from gene therapy to CRISPR, enabling it to deploy the right technology to the right disease and ensure the delivery of breakthrough treatments to millions of patients.
Both of its products, SPVN06 and SPVN20 go beyond single gene correction therapies to deliver new gene-agnostic treatments for Retinitis Pigmentosa, a group of inherited retinal diseases which are the leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology.
SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality international investors including 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and X (formerly Twitter) @SparingVision
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor (Rod derived Cone Viability Factor, RdCVF) and one enzyme reducing oxidative stress (Rod derived Cone Viability Factor Long form, RdCVFL). Acting synergistically, RdCVF and RdCVFL aim at slowing or stopping the degeneration of cone photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision’s primary disease targets are retinitis pigmentosa (RP), one of the most common inherited retinal diseases that affects an estimated two million patients worldwide and dry Age-related Macular Degeneration (AMD). There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases, where the loss of rods is known to be an early signal of the disease. SPVN06 is the result of decades of world-leading ophthalmology research by SparingVision founders José-Alain Sahel and Thierry Léveillard at the Paris Vision Institute.
 Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Centre de référence maladies rares REFERET, INSERM-DHOS CIC 1423, Paris, France
 Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France
3 Distinguished professor and chairman of the Department of Ophthalmology at the University of Pittsburgh School of Medicine and director of the UPMC Vision Institute
• No serious adverse events in the first two cohorts of pat…
Divestment of sepofarsen and ultevursen completed – Théa to …
ATSN-101 continues to demonstrate clinically meaningful impr…
RMAT designation recognizes the potential of ATSN-101 to add…
Data to be presented as part of gene augmentation therapy pr…
NVasc is developing a therapeutic angiogenesis strategy for …
Milestone broadens partnership to develop novel ocular thera…
OPGx-LCA5 is designed to address vision loss due to Leber co…
- Lead gene therapy asset, SPVN06, reported to be well-toler…
Amber Bio is developing a first-of-its-kind RNA writing plat…
Amber Bio’s proprietary platform leverages multi-kilobase RN…